232 related articles for article (PubMed ID: 27488049)
1. Oral bioavailability enhancement through supersaturation: an update and meta-analysis.
Fong SY; Bauer-Brandl A; Brandl M
Expert Opin Drug Deliv; 2017 Mar; 14(3):403-426. PubMed ID: 27488049
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability Improvement Strategies for Poorly Water-Soluble Drugs Based on the Supersaturation Mechanism: An Update.
Yang M; Gong W; Wang Y; Shan L; Li Y; Gao C
J Pharm Pharm Sci; 2016; 19(2):208-25. PubMed ID: 27518171
[TBL] [Abstract][Full Text] [Related]
3. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?
Brouwers J; Brewster ME; Augustijns P
J Pharm Sci; 2009 Aug; 98(8):2549-72. PubMed ID: 19373886
[TBL] [Abstract][Full Text] [Related]
4. Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating Formulations.
Sun DD; Lee PI
AAPS J; 2015 Nov; 17(6):1317-26. PubMed ID: 26338234
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis.
Fong SY; Brandl M; Bauer-Brandl A
Eur J Pharm Sci; 2015 Dec; 80():89-110. PubMed ID: 26296863
[TBL] [Abstract][Full Text] [Related]
6. Biorelevant dissolution testing and physiologically based absorption modeling to predict in vivo performance of supersaturating drug delivery systems.
Thakore SD; Sirvi A; Joshi VC; Panigrahi SS; Manna A; Singh R; Sangamwar AT; Bansal AK
Int J Pharm; 2021 Sep; 607():120958. PubMed ID: 34332060
[TBL] [Abstract][Full Text] [Related]
7. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2021 May; 17(5):555-580. PubMed ID: 33703995
[No Abstract] [Full Text] [Related]
8. Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.
Hens B; Bermejo M; Tsume Y; Gonzalez-Alvarez I; Ruan H; Matsui K; Amidon GE; Cavanagh KL; Kuminek G; Benninghoff G; Fan J; Rodríguez-Hornedo N; Amidon GL
Eur J Pharm Sci; 2018 Mar; 115():258-269. PubMed ID: 29378253
[TBL] [Abstract][Full Text] [Related]
9. Trends in the Assessment of Drug Supersaturation and Precipitation In Vitro Using Lipid-Based Delivery Systems.
Stillhart C; Kuentz M
J Pharm Sci; 2016 Sep; 105(9):2468-2476. PubMed ID: 26935881
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs.
Cerpnjak K; Zvonar A; Gašperlin M; Vrečer F
Acta Pharm; 2013 Dec; 63(4):427-45. PubMed ID: 24451070
[TBL] [Abstract][Full Text] [Related]
11. "Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.
Li YW; Zhang HM; Cui BJ; Hao CY; Zhu HY; Guan J; Wang D; Jin Y; Feng B; Cai JH; Qi XR; Shi NQ
Eur J Pharm Biopharm; 2021 Sep; 166():111-125. PubMed ID: 34119671
[TBL] [Abstract][Full Text] [Related]
12. Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs - a PEARRL review.
Jankovic S; Tsakiridou G; Ditzinger F; Koehl NJ; Price DJ; Ilie AR; Kalantzi L; Kimpe K; Holm R; Nair A; Griffin B; Saal C; Kuentz M
J Pharm Pharmacol; 2019 Apr; 71(4):441-463. PubMed ID: 29978475
[TBL] [Abstract][Full Text] [Related]
13. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
14. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
Porter CJ; Pouton CW; Cuine JF; Charman WN
Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
[TBL] [Abstract][Full Text] [Related]
15. Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.
Kleppe MS; Forney-Stevens KM; Haskell RJ; Bogner RH
AAPS J; 2015 Jul; 17(4):902-17. PubMed ID: 25851513
[TBL] [Abstract][Full Text] [Related]
16. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
17. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
18. Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs.
Karwal R; Garg T; Rath G; Markandeywar TS
Crit Rev Ther Drug Carrier Syst; 2016; 33(1):1-39. PubMed ID: 27279337
[TBL] [Abstract][Full Text] [Related]
19. Use of Spray-Dried Dispersions in Early Pharmaceutical Development: Theoretical and Practical Challenges.
Li J; Patel D; Wang G
AAPS J; 2017 Mar; 19(2):321-333. PubMed ID: 27896684
[TBL] [Abstract][Full Text] [Related]
20. Refining stability and dissolution rate of amorphous drug formulations.
Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
